CLINICAL STUDY

The effects of endothelial nitric oxide synthase gene polymorphisms on endothelial function and metabolic risk factors in healthy subjects: the significance of plasma adiponectin levels

Akiko Imamura, Ryotaro Takahashi, Ryuichiro Murakami, Hiroki Kataoka, Xian Wu Cheng, Yasushi Numaguchi, Toyoaki Murohara and Kenji Okumura

Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan, Cardiovascular Research Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan and Medical Science of Proteases, Nagoya University School of Medicine, Nagoya, Japan

(Correspondence should be addressed to K Okumura; Email: kenji@med.nagoya-u.ac.jp)

Abstract

Objective: Genetic variants of the endothelial nitric oxide synthase (eNOS) gene, Glu298Asp and T–786C, have been reported to be associated with cardiovascular disease. Adiponectin is an adipocyte-derived plasma protein with insulin-sensitizing and vascular protective effects; its levels are typically low in metabolic syndrome. Therefore, eNOS gene polymorphisms may also be associated with specific metabolic profiles, including plasma adiponectin levels and atherogenic lipids.

Methods: We evaluated the functional significance of eNOS gene Glu298Asp and T–786C polymorphisms on endothelial function and metabolic profiles in 101 healthy young men (mean age 30.3 years) before the progression of atherosclerotic lesions.

Results: No linkage disequilibrium was found between the two genotypes. The Asp298 allele carriers of the eNOS gene presented significantly higher plasma low density lipoprotein (LDL) cholesterol, LDL particle size, malondialdehyde-modified LDL (MDA-LDL), and fasting insulin levels and lower plasma high density lipoprotein (HDL) cholesterol, apolipoprotein A-I levels, and endothelium-dependent vasodilation when compared with noncarriers. In spite of higher MDA-LDL levels, Asp298 carriers had significantly larger LDL particle size. By contrast, in C–786 allele carriers, systolic blood pressure was significantly higher, and plasma high-molecular-weight adiponectin levels and endothelium-dependent vasodilation were significantly lower than those in non-carriers.

Conclusions: Although both eNOS polymorphisms induced endothelial dysfunction, the eNOS T–786C polymorphism may be associated with adiponectin levels, whereas the Glu298Asp polymorphism may be associated with atherogenic lipid levels.

European Journal of Endocrinology 158 189–195

Introduction

Metabolic syndrome, a cluster of the accumulation of visceral adipose tissue, insulin resistance, hyperglycemia, atherogenic dyslipidemia, and hypertension, has been suggested to contribute to the development of atherosclerosis and cardiovascular disease (1, 2). Adiponectin is an adipocyte-derived plasma protein, which has roles in preventing the development of atherosclerosis and the impairment of glucose and lipid metabolisms (3). Adiponectin expression and secretion from white adipose tissue are regulated by various factors including obesity, insulin-resistant status, and also some genetic backgrounds (4–6).

It has been reported that insulin stimulation of glucose uptake in skeletal muscle and adipose tissue in vivo is nitric oxide (NO) dependent in rats (7, 8). Other data have indicated that flow-induced dilation in visceral fat arterioles is NO dependent in the absence of known coronary artery disease (9). Recent animal data suggested that endothelial nitric oxide synthase (eNOS) knockout mice presented with a phenotype of insulin resistance, hypertension, and dyslipidemia, resembling that observed in human metabolic syndrome, especially under nutritional stress (10, 11).

In humans, several gene polymorphisms of eNOS have been detected; the eNOS G894T (Glu298Asp) and T–786C polymorphisms, in particular, are reported to be related to cardiovascular disease. These eNOS gene polymorphisms have also been associated with insulin-resistant state (12, 13), type 2 diabetes mellitus (14), higher plasma-oxidized low density lipoprotein (LDL) during acute phase of myocardial infarction (15), and metabolic syndrome (16). However, the effects of eNOS gene polymorphisms on metabolic profiles including plasma adiponectin and atherogenic lipid levels have not
been fully determined. The aim of the present study was to investigate phenotypic differences including differences in endothelial function and metabolic profile between two polymorphisms of eNOS, Glu298Asp and T–786C, in young healthy men before the expression of atherosclerotic diseases by genetic and environmental contributions.

**Subjects and methods**

**Study subjects**

We studied 101 young, apparently healthy men (mean age 30.3 ± 4.2 years; range 25–39 years). All subjects were volunteers, had no previous history of diabetes or cardiovascular disease, and received no medication. The study was approved by the Ethics Committee of Nagoya University and written informed consent was obtained from all subjects.

**Vascular study**

After overnight fasting, blood pressure was measured and assessment of brachial artery function was performed according to a previously described non-invasive technique (17). Using high-resolution ultrasound cardio-
graphy (SONOS 5500, Agilent Technologies Inc., Palo Alto, CA, USA), the end-diastolic diameter of the right brachial artery and blood flow by pulse wave Doppler ultrasound were measured. The diameter of the right brachial artery was measured from the anterior to the posterior interface between the media and adventitia, and the mean of three measurements was calculated.

Measurements of flow-mediated dilation (FMD), an endothelium-dependent response, were taken at baseline, then at 1 min after forearm hyperemia (produced by releasing a forearm cuff inflated to 250 mmHg for 5 min), and finally at rest after the subject had been lying quietly for 10 min. Then, after the diameter was recovered to the level of the baseline diameter, glyceryl trinitrate-induced dilation (GTN), an endothelium-independent dilation, was assessed 3 and 5 min after sublingual application of 300 μg glyceryl trinitrate.

Participants were asked to refrain from smoking within 24 h of the measurement.

**Biochemical analyses**

In all subjects, an overnight fasting venous blood sample was obtained on the same day as flow measurements. Standard assays were used to measure serum concentrations of total cholesterol, high density lipoprotein (HDL) cholesterol, LDL cholesterol, and triglycerides as well as insulin, glucose, and HbA1c levels. For estimation of insulin sensitivity, a homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. Plasma total adiponectin and high-molecular-weight (HMW) adiponectin concentrations were measured by sandwich ELISA (Otsuka Pharmaceuticals, Tokyo, Japan and Fujirebio, Tokyo, Japan respectively) as previously described (18).

**Genotyping of the eNOS Glu298Asp and T–786C polymorphisms**

Genomic DNA was prepared from peripheral blood leukocytes using a QIAamp DNA blood minikit (Qiagen). Genotypes for the Glu298Asp and T–786C polymorphisms were determined by PCR-restriction fragment length polymorphism analysis using specific oligonucleotide primers (Glu298Asp: sense, 5'-AAC ACT TTC CTG AGC-3' and anti-sense, 5'-CTT ATC CTG ACA CAT TTT GAG A-3'; T–786C: sense, 5'-CAT TCT GGG AAC TGT-3' and anti-sense, 5'-GTC AGC AGA GAG ACT-3'). PCR products were digested by BanII and MspI for the Glu298Asp and T–786C polymorphisms respectively and were separated by a 2.5% agarose gel and an 8% polyacrylamide gel for the Glu298Asp and T–786C polymorphisms respectively.

**LDL particle size**

EDTA plasma samples were stored frozen at −70 °C until analysis. The LDL particle size was determined by electrophoresis using non-denaturing 4–14% polyacrylamide gradient gels with modified methods (19). In brief, 7.5 μl plasma samples were applied on gels with a final concentration of 20% sucrose and 0.25% bromophenol blue. After electrophoresis, the gels were scanned (CS9300; Shimadzu Co., Kyoto, Japan) and migration distances (from the top of the gel to the most prominent band) were measured. The apparent diameters of major LDL particles were measured by comparing results with a calibration curve constructed with ferritin, thyroglobulin, and latex beads. The estimated diameter for the major peak in each scan was identified as the LDL particle size.

**Malondialdehyde-LDL (MDA-LDL)**

The ELISA used for measurement of MDA-LDL was based on the method reported by Kotani et al. (20). In brief, microtiter plates were coated with a monoclonal antibody against apoB. Duplicate 100 μl samples were added to the wells of the plates and incubated. After washing, a β-galactosidase-conjugated monoclonal antibody against apoB was added to each well. After washing, 100 μl substrate solution, 0-nitrophenyl-β-galactopyranoside (10 mmol/l), was dispensed into each well and allowed to react. The reaction was terminated by a stop solution, and absorbance was determined spectrophotometrically at 415 nm.

**Statistical analysis**

Data are reported as mean ± S.D. Data were analyzed using the StatView 5.0 software program (SAS...
Institute, Cary, NC, USA). Continuous variables were tested for normal distribution by the Kolmogorov–Smirnov test. When data were not normally distributed (i.e., triglycerides, fasting insulin, and HOMA-IR), they were logarithmically transformed before statistical analysis. The χ²-test was used for genetic linkage between the two eNOS polymorphisms, and multilocus haplotype frequencies were estimated using the iterative expectation maximization algorithm (21). The unpaired Student’s t-test was used to calculate the statistical significance between the presence and absence of the Asp296 or C–786 allele. A value of $P<0.05$ was considered statistically significant.

**Results**

**Baseline characteristics of study participants and genotype frequencies of eNOS polymorphisms**

Table 1 shows the clinical characteristics of study participants. Of the 101 subjects enrolled in the study, 9 had hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg), 8 had hypercholesterolemia (total cholesterol >6.2 mmol/l and/or LDL cholesterol >4.1 mmol/l), and 15 had hypertriglycemia (>1.7 mmol/l). There was only one subject with hyperinsulinemia (>240 mmol/l). Sixteen subjects had obesity (body mass index, BMI >25 kg/m²). Study subjects were relatively young, apparently healthy, and neither took medication nor had ever been diagnosed with diabetes or cardiovascular disease. Two subjects had fasting glucose levels above 7.0 mmol/l.

Table 2 Genotype distribution and association of the eNOS Glu298Asp and T–786C polymorphisms.

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Glu298Asp</th>
<th>T–786C</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Glu/Glu (G/G)</td>
<td>Glu/Asp (G/T)</td>
</tr>
<tr>
<td>T/T</td>
<td>61</td>
<td>16</td>
</tr>
<tr>
<td>T/C</td>
<td>14</td>
<td>5</td>
</tr>
<tr>
<td>C/C</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>76</td>
<td>21</td>
</tr>
</tbody>
</table>

There was no linkage disequilibrium between the Glu298Asp and T–786C polymorphisms by the expectation maximization algorithm for haplotype inference ($d=7\times10^{-7}$) and by the χ²-analysis ($\chi^2=0.007, P=0.93$).

**Effects of the eNOS Glu298Asp and T–786C polymorphisms on vascular study**

Endothelial NO production was assessed by comparing FMD in response to flow with GTN in the brachial artery. Namely, to normalize the changes in FMD for changes due to glyceryl trinitrate instead of comparing the absolute changes in FMD, the ratio of FMD to GTN (FMD/GTN) was calculated (23). Both the Asp298 and the C–786 significantly reduced endothelium-dependent vasodilation by 26% ($P=0.02$) and 23% ($P=0.05$) respectively, indicating that the alleles inhibit the endothelial function to the same extent (Tables 3 and 4).

**Differences in clinical characteristics assigned to eNOS genotypes**

Clinical characteristics were shown in Tables 3 and 4 between two subgroups that are divided according to the presence of Asp298 or C–786 alleles respectively. In the Asp298 carriers, plasma LDL cholesterol ($P=0.04$), LDL particle size ($P=0.003$), and MDA-LDL ($P=0.05$), fasting insulin ($P=0.04$), and HOMA-IR values ($P=0.04$) were significantly higher than those in the non-carriers. Plasma HDL cholesterol ($P=0.01$) and apolipoprotein A-I levels ($P=0.003$) were significantly higher.
Plasma fasting insulin, HOMA-IR value, and total adiponectin had a tendency toward higher levels in carriers of the C–786 allele than in non-carriers. When we compared variables in subjects with both alleles (n = 5) to those in the others (n = 96), there was a significant difference only in FMD/HTN (0.17 ± 0.04 vs 0.31 ± 0.14, P = 0.04).

Table 4 Physical and biochemical characteristics of subjects assigned by the presence of the eNOS C-786 allele.

<table>
<thead>
<tr>
<th>eNOS T–786C</th>
<th>T/T (n=81)</th>
<th>T/C or C/C (n=20)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>30.3 ± 4.3</td>
<td>30.3 ± 3.9</td>
<td>0.99</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.1 ± 2.6</td>
<td>22.4 ± 2.3</td>
<td>0.28</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>119.7 ± 11.6</td>
<td>126.1 ± 12.9</td>
<td>0.036</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>71.2 ± 8.7</td>
<td>73.0 ± 10.7</td>
<td>0.44</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>4.87 ± 0.77</td>
<td>4.96 ± 0.76</td>
<td>0.66</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/l)</td>
<td>1.52 ± 0.34</td>
<td>1.47 ± 0.24</td>
<td>0.52</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/l)</td>
<td>2.95 ± 0.68</td>
<td>3.00 ± 0.70</td>
<td>0.80</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.27 ± 1.11</td>
<td>1.96 ± 2.79</td>
<td>0.33</td>
</tr>
<tr>
<td>LDL particle size (nm)</td>
<td>263.4 ± 9.6</td>
<td>260.6 ± 11.1</td>
<td>0.26</td>
</tr>
<tr>
<td>MDA-LDL (U/L)</td>
<td>111.3 ± 51.1</td>
<td>90.5 ± 40.2</td>
<td>0.11</td>
</tr>
<tr>
<td>Apolipoprotein A-I (mg/dl)</td>
<td>138.5 ± 20.5</td>
<td>136.1 ± 18.4</td>
<td>0.63</td>
</tr>
<tr>
<td>Apolipoprotein B (mg/dl)</td>
<td>83.2 ± 18.6</td>
<td>84.4 ± 20.1</td>
<td>0.81</td>
</tr>
<tr>
<td>Fasting glucose (mmol/l)</td>
<td>5.41 ± 0.61</td>
<td>5.13 ± 0.27</td>
<td>0.050</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>4.70 ± 0.30</td>
<td>4.67 ± 0.24</td>
<td>0.62</td>
</tr>
<tr>
<td>Fasting insulin (pmol/l)</td>
<td>68.4 ± 54.6</td>
<td>47.4 ± 20.4</td>
<td>0.096</td>
</tr>
<tr>
<td>HOMA-IR value</td>
<td>2.9 ± 2.9</td>
<td>1.8 ± 0.8</td>
<td>0.067</td>
</tr>
<tr>
<td>Total adiponectin (µg/ml)</td>
<td>7.7 ± 3.7</td>
<td>6.1 ± 2.8</td>
<td>0.075</td>
</tr>
<tr>
<td>HMW adiponectin (µg/ml)</td>
<td>4.1 ± 2.5</td>
<td>2.8 ± 1.6</td>
<td>0.026</td>
</tr>
<tr>
<td>FMD</td>
<td>4.81 ± 2.50</td>
<td>3.99 ± 1.54</td>
<td>0.17</td>
</tr>
<tr>
<td>GTN</td>
<td>15.89 ± 5.27</td>
<td>17.80 ± 4.40</td>
<td>0.13</td>
</tr>
<tr>
<td>FMD/HTN</td>
<td>0.31 ± 0.15</td>
<td>0.24 ± 0.12</td>
<td>0.045</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± s.o. BMI, body mass index; MDA-LDL, malondialdehyde-LDL; HOMA-IR, homeostasis model assessment of insulin resistance; HMW, high-molecular-weight; FMD, flow-mediated dilatation; GTN, glyceryl trinitrate-induced dilatation. Triglycerides, fasting insulin, and HOMA-IR were logarithmically transformed before statistical analysis.
Discussion

Extensive epidemiologic evidence has consistently indicated that alterations of endothelial function play a pivotal role in the development of atherosclerosis and predict the occurrence of atherosclerotic complications (24, 25). Accumulated evidence strongly suggests that eNOS gene polymorphisms are associated with the bioavailability of eNOS and endothelial function (26–28). However, differences in biochemical phenotypes and clinical findings among the polymorphisms have not yet been fully elucidated. In the present study, to gain insight into the underlying mechanisms by which the presence of the Asp298 or C–786 allele impairs endothelial function, we recruited young, healthy, preclinical subjects, and analyzed how physical and biochemical variables were related to each eNOS gene variant. There are marked differences in the distribution of eNOS polymorphisms among races, and our results are consistent with the previous study (26). Although the two polymorphisms were independent, we found a significantly close relationship between endothelial function and both the Glu298Asp and T–786C polymorphisms, as previously reported (27, 28), and suggested that there is a distinct difference in the biological function of the Asp298 and C–786 alleles. Interestingly, the presence of the C–786 allele was significantly closely associated with adiponectin, and particularly HMW adiponectin, while it had little effect on other physical and biochemical variables. Conversely, the Asp298 allele did not affect any adiponectin levels, but adversely altered the atherogenic lipid profile. Namely, the Asp298 allele induced an increase in plasma LDL cholesterol, MDA-LDL, and fasting insulin levels, and decrease in HDL cholesterol.

To our knowledge, this is the first study to determine the relationship between eNOS gene polymorphisms and plasma adiponectin levels. Adiponectin is an adipocyte-specific secreted protein that is highly expressed in adipose tissue and circulates in plasma at high concentrations. Plasma adiponectin includes three forms: a low-molecular-weight trimer, a medium-molecular-weight hexamer, and a larger HMW multimer. So far, plasma adiponectin levels have been shown to have an inverse relationship with visceral fat accumulation and insulin resistance (34), and the plasma HMW adiponectin level, rather than the absolute amount of adiponectin, has been reported to be the key in determining insulin sensitivity (35).

Plasma HMW adiponectin reduction by the presence of the C–786 allele was significantly accompanied by an increase in systolic blood pressure, and there was a tendency toward lower fasting plasma glucose and HOMA-IR values. Hypoadiponectinemia is reported to predict the development of hypertension in normotensive subjects (36). In the case of C–786 allele carriers in this study, a decrease in plasma adiponectins may precede increased blood pressure and decreased peripheral circulation in adipose tissues. The precise mechanism of decreased adiponectin levels remains to be elucidated although the decreased amount of eNOS protein may be related to plasma adiponectins. In terms of the Asp298 allele, it appears that replacement of one nucleotide alters the eNOS quality rather than the quantity of eNOS production, and as a result, this polymorphism showed no relationship with adiponectin levels. Taken together, the two polymorphisms had similar effects on endothelial function, but the mechanism underlying the impairment of endothelial function in each case may be entirely different.

Few studies have reported a significant relationship between eNOS polymorphisms and serum lipid profiles (37). The reason is that most previous reports have analyzed subjects over 40 years old with overt vascular disease. In the present study, we recruited only young healthy men without apparently overt cardiovascular disease. In the present study, we recruited only young healthy men without apparently overt cardiovascular disease to avoid the environment factors and other genetic factors such as dyslipidemia and hypertension that emerge with aging. Recent data have suggested that Asp variants of the Glu298Asp polymorphism resulted in impaired response to shear (38). eNOS activation is associated with an increase in the L-arginine transport protein in the endothelial caveolae (39). In addition, caveolae are very important for lipid metabolism, and are proposed to play a major role in the transcytosis of native...
and modified LDL (40). HDL maintains the concentration of caveolae-associated cholesterol, thereby preventing the negative impact of oxidized LDL. In the presence of the Asp298 allele, the action of the produced eNOS may be different from that of the normally constituted eNOS, and therefore may alter plasma lipid profiles and insulin resistance. In the present study, we encountered only four homozygotes for the Asp298 allele, and their levels of HDL cholesterol and apolipoprotein A-I were significantly lower (1.09 ± 0.24 vs 1.42 ± 0.24 mmol/ml, 109.0 ± 18.6 vs 131.4 ± 16.1 mg/dl respectively), while their fasting insulin and HOMA-IR levels were significantly higher (141 ± 72 vs 69 ± 49 pmol/L, 5.8 ± 2.7 vs 3.0 ± 2.8 respectively) than respective values for heterozygotes, suggesting that the additional effects of the Asp298 allele in homozygotes were due to increased production of the structurally changed eNOS protein. Characteristics of metabolic syndrome as represented by hyperinsulinemia and lowered plasma HDL cholesterol were observed in Asp298 allele carriers. Evidence that Asp298 allele carriers are susceptible to hyperinsulinemia and higher HOMA-IR values has already been reported (14), and eNOS gene polymorphisms including these alleles are associated with features of metabolic syndrome such as insulin resistance, hypertriglyceridemia, and low HDL cholesterol concentrations (16).

Surprisingly, we observed an increase in LDL particle size in Asp298 allele carriers. The variable most closely related to LDL particle size in the present study was plasma triglyceride levels ($r=0.372$, $P<0.001$) as previously reported (41). At present, the reason why LDL particle size was elevated in Asp298 allele carriers cannot be explained.

The present study was limited because of the small number of subjects. However, since the two polymorphisms affect endothelial function independently, subjects with both the Asp298 and C-786 alleles must pay more attention to the prevention of atherosclerosis development.

It is concluded that the two polymorphisms of the eNOS gene affect endothelial functions to the same degree, but differently: namely, that the eNOS T–786C polymorphism may determine adiponectin levels in adipose tissue, whereas the Glu298Asp polymorphism may be associated with lipid levels and other metabolic risk factors via both local regulation of blood flow in peripheral tissue and oxidative stress. The phenotypes associated with both polymorphisms are involved in the clinical features of metabolic syndrome, suggesting that the eNOS gene and NO are closely associated with metabolic status.

References


6 Santanieni M, Kesaniemi YA & Ukkola O. Low plasma adiponectin concentrations is an indicator of the metabolic syndrome. European Journal of Endocrinology 2006 155 745–750.


13 Tso AWK, Tan KCB, Wat NMS, Janus ED, Lam TH & Lam KSL. Endothelial nitric oxide synthase G894T (Glu298Asp) polymorphism was predictive of glycemic status in a 5-year prospective study of Chinese subjects with impaired glucose tolerance. Metabolism 2006 55 1155–1158.


Received 24 October 2007
Accepted 7 November 2007

www.eje-online.org